Medinol introduces NIRxcell CoCr Stent System to coronary marketplace

December 1, 2015

During the recent 2015 Transcatheter Cardiovascular Therapeutics Meeting held in San Francisco, CA, Medinol Ltd. continued to introduce novel stent solutions to the coronary marketplace. During a satellite symposium, "The BioNIR eDES: The Role of Uniformity in Stent Design to Minimize Restenosis", a renowned physician panel discussed the key attributes of the currently available Medinol NIRxcell CoCr Coronary Stent System and the Medinol eDES Coronary Stent System (in trials, not FDA/CE Mark approved).

Previous Article
Larger portion of Africa at high risk for malaria transmission
Larger portion of Africa at high risk for malaria transmission

A larger portion of Africa is currently at high risk for malaria transmission than previously predicted, ac...

Next Article
Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD
Synthetic Biologics announces positive results from first SYN-004 Phase 2a study for prevention of CDI, AAD

Synthetic Biologics, Inc.), a clinical stage company focused on developing therapeutics to protect the gut ...